other material
confidence high
sentiment positive
materiality 0.50
Nuvectis Pharma reports $24.5M cash, runway into H1 2025
Nuvectis Pharma, Inc.
- Cash and equivalents of $24.5M at June 30, 2023, up ~$9.0M from March 31, 2023.
- Increase primarily from exercise of previously issued preferred investment options in Q2 2023.
- Company estimates current cash sufficient to fund planned operations into first half of 2025.
- Cash figure is preliminary, subject to change upon completion of period-end close.